SAN FRANCISCO, Nov. 2, 2011 /PRNewswire/ -- Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic products for cancer, today announced that final data from its Phase 2 randomized clinical trial in advanced liver cancer patients will be presented on Monday, November 7, 2011 at the 62nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) taking place November 4-8, 2011 in San Francisco, California. These data, evaluating multi-dose administration of JX-594 in U.S., Korean and Canadian patients with advanced liver cancer, were selected for an oral presentation in the late-breaking oral session of the conference.
The presentation details are as follows:
Abstract Title: "A Randomized, Controlled Phase 2 Clinical Trial of JX-594, a Targeted Multi-Mechanistic Oncolytic Poxvirus, in Patients with Advanced Hepatocellular Carcinoma: Final Data." (Abstract #LB1)
Presenter: Tony Reid, M.D., Ph.D., professor of medicine, hematology/oncology, director of clinical investigation, and the tumor growth, invasion and metastasis program, Moores UCSD Cancer Center at the University of California, San Diego
Session: Late-Breaking Oral Session, November 7, 2011, 2:45 p.m. PT
JX-594: A Multi-Mechanistic Approach To Targeting Cancer
JX-594 is a proprietary, engineered oncolytic virus that is designed to selectively target and destroy cancer cells. JX-594 is designed to attack cancer through three diverse mechanisms of action: 1) the lysis of cancer cells through viral replication, 2) the shutdown of the blood supply to tumors through vascular targeting and destruction, and 3) the stimulation of the body's immune response against cancer cells, i.e., active immunotherapy. Phase 1 and Phase 2 clinical trials in multiple cancer types to date have shown that JX-594, delivered either directly into
|SOURCE Jennerex, Inc.|
Copyright©2010 PR Newswire.
All rights reserved